Climb Bio said it presented initial Phase 1 data for investigational therapy CLYM116 on Sept. 3, marking an early clinical milestone. The company disclosed no further details on the results or pipeline impact.
published
Climb Bio said it presented initial Phase 1 data for investigational therapy CLYM116 on Sept. 3, marking an early clinical milestone. The company disclosed no further details on the results or pipeline impact.
Latest documented BWB result
$META market result
I sold the $META $655 Puts 9/25 for $7.60
Historical results are not a promise of future performance. Trading involves substantial risk.This public post is a timestamped information archive, not personalized financial advice. Alerts can change as markets move. Join Billy's private group for the complete daily stream and follow-through.